Featured Exclusive
An educational activity designed by i3 Health has demonstrated significant learning gains in the treatment and management of myelodysplastic syndromes (MDS) and has been presented at the 2021 Greater Los Angeles Oncology Nursing Society (GLAONS) Oncology Care Summit. A group of myeloid clonal hematopoietic disorders with a relatively heterogeneous spectrum of presentation, MDS, is associated with clinical problems resulting from cytopenias, which can evolve into acute myeloid leukemia. The incid...
Expert Analysis
· In this podcast, Dr. Steven Horwitz of Memorial Sloan Kettering Cancer Center discusses recent progress in the treatment and management of T-cell lymphoma. Listen now to hear more!...
· Keira Smith: Welcome to Oncology Data AdvisorTM, where we explore the latest advances in cancer research and treatment. I'm Keira Smith. In this podcast, Dr. Sara Tolaney from Dana-Farber Cancer Institute will be discussing strategies for improving the management of patients with metastatic breast cancer. Thank you for joining us, Dr. Tolaney. Sara Tolaney, MD, MPH: Thanks so much for hav...
Keira Smith: Hi. I'm Keira Smith from Oncology Data Advisor. I'm here today with Allison Imahiyerobo. Allison Imahiyerobo: Hi Keira, my name is Alli Imahiyerobo. I'm a nurse practitioner, and I practice at Hematology Oncology Physicians of Englewood in New Jersey. I focus on both benign and malignant hematology. Keira Smith: What are some of the most challenging aspects of treating patients with i...
Welcome to Oncology Data Advisor, where we explore the latest advances in cancer research and treatment. I am Selma Khenissi from i3 Health. In this podcast, Dr. Kelly Brassil, PhD, RN, from The University of Texas MD Anderson Cancer Center, will be discussing patient-reported symptom data and how it affects patient survival and quality of life. Selma Khenissi, MPS: Can you comment on how tools su...
In this interview, Steven Horwitz, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, speaks with Oncology Data Advisor about the recent advancements in the treatment of T-cell lymphoma. Keira Smith: Hi, I'm Keira Smith from Oncology Data AdvisorTM. I'm here today with Dr. Steven Horwitz. Steven Horwitz, MD: Hi, pleasure to be here. I'm Dr. Steven Horwitz. I'm a medical ...
Keira Smith: Hi, I'm Keira Smith from Oncology Data AdvisorTM. I'm here today with Dr. Sara Tolaney. Sara Tolaney, MD, MPH: Thanks so much for having me. I'm Sara Tolaney. I'm a breast medical oncologist at Dana-Farber Cancer Institute here in Boston. Keira Smith: Thank you so much for joining us, Dr. Tolaney. So what are some of the most challenging aspects of managing patients with metastatic br...
Podcast Spotlight
Practice Patterns
An educational activity designed by i3 Health has demonstrated significant learning gains in the treatment and management of myelodysplastic syndromes (MDS) and has been presented at the 2021 Greater Los Angeles Oncology Nursing Society (GLAONS) Oncology Care Summit. A group of myeloid clonal hematopoietic disorders with a relatively heterogeneous spectrum of presentation, MDS, is associated with ...
Follicular lymphoma, an indolent, difficult-to-treat B-cell malignancy, is complicated by evolving disease subtypes. Patient outcomes can be hampered by the failure of the multidisciplinary team to establish consensus on the optimal timing, schedule, and length of follicular lymphoma treatment. In addition, the rapid pace of research makes it difficult to stay abreast of the latest and most clinic...
Lung cancer is diagnosed in approximately 235,760 individuals in the United States each year, and 131,880 people die of the disease annually. Non-small cell lung cancer (NSCLC), which accounts for 84% of these cases, has a dismal 5-year survival rate of 18%, and most patients will develop progressive disease within 5 months of their final cycle of first-line classical doublet chemotherapy. The use...
Myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocytopenia, affect approximately 13,000, 134,000, and 148,000 individuals in the United States, respectively. Due to difficulties in identifying the disease, low disease prevalence, a complicated symptom profile, differences in patient and provider perspectives regarding symptom burden and treatment goals...
A shortfall in knowledge in the use of biomarkers and patient-related factors for the personalization of treatment for patients with advanced urothelial carcinoma was identified in the baseline data collected from i3 Health's continuing medical education (CME)–approved visiting faculty meeting series titled New Thinking, New Strategies in Advanced Urothelial Carcinoma, led by Arjun V. Balar, MD, A...
When patients with hematological malignancies do not receive referrals for hematopoietic stem cell transplant (HSCT), they may face a risk of poorer outcomes. Common reasons behind this lack of referrals include provider confusion over eligibility criteria for HSCT, overestimation of the risks associated with transplant, and confusion regarding the benefit of HSCT. This educational gap regarding t...
Noteworthy Headlines
Friday, September 17, 2021
The FDA has approved mobocertinib (Exkivity™, Takeda) for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion...
Thursday, September 16, 2021
The FDA has granted accelerated approval to zanubrutinib (Brukinsa®, BeiGene) for the treatment of patients with relapsed/refractory marginal zone lymphoma (MZL) who have received at least one anti–CD...
Friday, September 10, 2021
· In this podcast, Dr. Steven Horwitz of Memorial Sloan Kettering Cancer Center discusses recent progress in the treatment and management of T-cell lymphoma. Listen now to hear more!...
Tuesday, September 07, 2021
· Keira Smith: Welcome to Oncology Data AdvisorTM, where we explore the latest advances in cancer research and treatment. I'm Keira Smith. In this podcast, Dr. Sara Tolaney from Dana-Farber Can...
Friday, September 03, 2021
The FDA has granted approval to zanubrutinib (Brukinsa®, BeiGene) for the treatment of patients with Waldenstrom macroglobulinemia (WM). "Bruton tyrosine kinase (BTK) inhibition is an emerging standar...
Most Popular
